Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$9.19 -0.6%	$18.67	$54.95 ▼ $105.00	$266.37M	0.95	12,894 shs	4.17 million shs
DRUG Bright Minds Biosciences	$23.27 -6.1%	$29.56	$0.93 ▼ $79.02	$163.82M	-5.74	825,038 shs	627,261 shs
NVCT Nuvectis Pharma	$7.55 -2.1%	$9.15	$4.44 ▼ $11.80	$157.72M	-0.16	132,669 shs	1.87 million shs
STTK Shattuck Labs	$0.85 -14.6%	$1.00	$0.69 ▼ $4.99	$40.89M	1.72	331,240 shs	5.08 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-7.08%	+29.62%	-89.54%	-84.18%
DRUG Bright Minds Biosciences	0.00%	-14.79%	-10.50%	-35.49%	+2,045.49%
NVCT Nuvectis Pharma	0.00%	-7.13%	-17.67%	-22.72%	+19.27%
STTK Shattuck Labs	0.00%	-10.78%	-16.30%	-10.15%	-77.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	3.1934 of 5 stars	3.6	3.0	0.0	0.0	4.0	2.5	0.0
NVCT Nuvectis Pharma	2.9507 of 5 stars	3.5	0.0	0.0	0.0	2.8	5.0	0.6
STTK Shattuck Labs	3.3748 of 5 stars	3.4	4.0	0.0	0.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	257.76% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	125.17% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.50	778.53% Upside

Current Analyst Ratings Breakdown

Latest STTK, NVCT, DRUG, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/30/2025	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $15.00
4/2/2025	NVCT Nuvectis Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.50 per share	N/A
STTK Shattuck Labs	$5.72M	7.15	N/A	N/A	$1.67 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.13	N/A	N/A	N/A	N/A	-148.83%	-95.60%	8/5/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.39	N/A	N/A	N/A	-1,156.46%	-79.69%	-69.13%	7/30/2025 (Estimated)

Latest STTK, NVCT, DRUG, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	-$0.27	+$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	STTK Shattuck Labs	-$0.29	-$0.27	+$0.02	-$0.27	N/A	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Latest STTK, NVCT, DRUG, and AVTE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
DRUG Bright Minds Biosciences	N/A	126.01	126.01
NVCT Nuvectis Pharma	N/A	3.28	3.28
STTK Shattuck Labs	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
DRUG Bright Minds Biosciences	40.52%
NVCT Nuvectis Pharma	96.77%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
DRUG Bright Minds Biosciences	42.66%
NVCT Nuvectis Pharma	30.52%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
NVCT Nuvectis Pharma	8	20.89 million	14.52 million	Not Optionable
STTK Shattuck Labs	100	47.90 million	42.15 million	Optionable

STTK, NVCT, DRUG, and AVTE Headlines

Recent News About These Companies

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Rating of "Moderate Buy" from Analysts

June 30 at 3:09 AM | americanbankingnews.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28 at 11:27 PM | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | globenewswire.com

Shattuck Labs Full Year 2024 Earnings: Misses Expectations

March 29, 2025 | uk.finance.yahoo.com

Shattuck Labs reports Q4 EPS (37c), consensus (32c)

March 28, 2025 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)

March 28, 2025 | markets.businessinsider.com

Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | finanznachrichten.de

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | globenewswire.com

Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation

March 18, 2025 | msn.com

Shattuck Labs initiated with an Outperform at Leerink

March 17, 2025 | markets.businessinsider.com

Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

March 11, 2025 | finance.yahoo.com

H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)

February 21, 2025 | markets.businessinsider.com

Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

February 20, 2025 | markets.businessinsider.com

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 20, 2025 | globenewswire.com

Shattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in Berlin

February 13, 2025 | quiverquant.comQ

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 13, 2025 | globenewswire.com

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

STTK, NVCT, DRUG, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$9.19 -0.06 (-0.65%)

As of 06/27/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$23.27 -1.51 (-6.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$24.39 +1.12 (+4.81%)

As of 09:13 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Nuvectis Pharma NASDAQ:NVCT

$7.55 -0.16 (-2.08%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.55 +0.00 (+0.01%)

As of 08:50 AM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Shattuck Labs NASDAQ:STTK

$0.85 -0.15 (-14.63%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.89 +0.03 (+4.02%)

As of 09:21 AM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time